Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
News|Articles|March 17, 2026
Transforming Bladder Cancer Treatment: The Rise of Immunotherapy in Community Oncology Practices
This insight piece explores how treatment patterns in bladder cancer have shifted as immunotherapy options have expanded in community oncology. You’ll learn how combination regimens such as enfortumab vedotin–pembrolizumab have become more widely used, what real world data shows about changes in first line treatment choices, and how duration on therapy differs across approaches. It offers a real-world look at how community providers are adapting to new evidence and incorporating emerging options into care.
Related to this article
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
FDA has granted accelerated approval to Ultomiris based on Phase III data showing a 43.4% placebo-adjusted reduction at 34 weeks.
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Trending on PharmExec
1
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
4
Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
5